# Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

> **NCT01193062** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-04995274
- **DRUG:** PF-04995274

## Key facts

- **NCT ID:** NCT01193062
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193062, "Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01193062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*